Research Studies and Protocols

Research Studies and Protocols for Lung Cancer Where Faculty Members of the Lung Cancer Evaluation Center Participate:

National Lung Cancer Trials Available at Stony Brook:

OSI  – Phase III Study (www.osip.com)

Tarceva® (Erlotinib) HER1/EGFR inhibitors study of adjuvant therapy for non-small cell lung cancer Stage 1B, incidentally found Stage IIIA.  The goal is to see if specifically targeted therapy prevents the recurrence of lung cancer after resection in early stage lung cancers. 

The Radiant Trial, which is now enrolling patients in phase III clinical trials testing Tarceva® as an adjuvant therapy in patients who have undergone surgery for non-small cell lung cancer with EGFR positive tumors. 

Pfizer Pharmaceuticals-Phase II Study

A randomized trial of erlotinib with or without PF-3512676 for the treatment of patients with advanced EGFR-Positive Non-Small Cell Lung Cancer after failure of at least one prior chemotherapy regimen.

Sponsored by the American College of Surgeons Oncology Group (www.acosog.org)

Z4033– A pilot study of radiofrequency ablation in high risk patients with Stage IA non-small cell lung cancer

RTOG 0813 – A seamless phase I/II study of stereotactic lung radiotherapy (SBRT) for early stage centrally located non-small cell lung cancer in medically inoperable patients. 

Local Trials Available at Stony Brook:

Tumor Banking

All patients who undergo surgery at Stony Brook University Hospital are eligible to participate.  Part of their removed cancers will be placed in a tumor bank where the tissue is preserved after it has been analyzed by the pathologist for testing of treatment that may become available in the future, and for cancer research purposes. 

Cancer Registry

The identified patient data is collected prospectively with a blood sample and correlated to the above named tumor bank specimens for genetic testing and related research associated with lung cancer. 

Lung Cancer Trials Not Available at Stony Brook:

Z4032 – Randomized phase III study of sub-lobar resection versus sub-lobar resection plus brachytherapy with mesh  in high risk patients with non-small cell lung cancer 3 cm or smaller

CALBG 140503 – A phase III randomized trial of lobectomy versus sub-lobar resection for small (equal 2 cm) peripheral non-small lung cancer

RTOG 0618 – A phase II trial of stereotactic body radiation therapy (SBRT) in the treatment of patients with operable Stage I/II non-small lung cancer.  (www.RTOG.org). 

For more information to find out if a study not listed on this page is enrolling patients in your area, please visit www.clinicaltrials.gov.  Another helpful resource to our patients, and to learn more about cancer clinical trials, please visit www.CancerTrialsHelp.org.